Antifungal therapy strategies in hematopoietic stem-cell transplant recipients: early treatment options for improving outcomes.
Changes in clinical practice permit more patients to undergo hematopoietic stem-cell transplantation but also have increased the risk for invasive fungal infection (IFI) in this population. Given the difficulties in the diagnosis of fungal infection and the correlation between delays in therapy and poor outcome, earlier treatment, and prophylactic strategies are attractive options for the management of IFIs in high-risk patients. The selection of the most effective antifungal treatment strategy requires a thorough knowledge of IFI risk factors, potential causative organisms, and the safety and efficacy of appropriate antifungal agents.
Chandrasekar
Pranatharthi
P
Division of Infectious Diseases, Wayne State University School of Medicine, Karmanos Cancer Institute/Harper University Hospital, Detroit, MI 48201, USA. pchandrasekar@med.wayne.edu
Ljungman
Per T
PT
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D001393:Azoles / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D009181:Mycoses / Q000517:prevention & control*; D012306:Risk; D012307:Risk Factors; D016896:Treatment Outcome
D000935:Antifungal Agents; D001393:Azoles